ARICEPT

Compare ARICEPT  to:
Compare
Compare

Generic Name for ARICEPT

Donepezil HCl 5mg, 10mg; tabs.

Legal Classification:

Rx

Pharmacological Class for ARICEPT

Reversible acetylcholinesterase inhibitor (piperidine deriv).

Manufacturer of ARICEPT

Eisai Pharmaceuticals

Indications for ARICEPT

Alzheimer's dementia.

Adult dose for ARICEPT

Mild-moderate: Initially 5mg daily at bedtime. Severe: 10mg daily at bedtime. All: may increase to 10mg daily after 5mg dose given for 4–6 weeks. ODT: dissolve on tongue, then drink water.

Children's dosing for ARICEPT

Not applicable.

Also:

Precautions for ARICEPT

Cardiac conduction conditions. Monitor for GI bleeding. Seizures. Asthma. Pregnancy (Cat.C). Nursing mothers.

Interactions for ARICEPT

Drugs that affect CYP2D6 and CYP3A4 may affect rate of elimination. Antagonizes anticholinergics. May potentiate succinylcholine-type muscle relaxants, other cholinesterase inhibitors, cholinergic agonists (eg, bethanecol). Concomitant NSAIDs may increase risk of GI bleed.

Adverse Reactions for ARICEPT

GI upset, insomnia, muscle cramps, fatigue, anorexia.

How is ARICEPT supplied?

Tabs—30, 90
ODT—30

Related Disease:

Alzheimer's dementia

Related Resources

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

FDA accepts NDA for extended release Aricept, a treatment for Alzheimer's disease (AD)

November 25, 2009

Eisai and Pfizer announced that the FDA has accepted for review the New Drug Application (NDA) for once-daily 23 mg Aricept (donepezil HCl extended release tablets) for the treatment of moderate to severe Alzheimer's disease (AD).

Phase 3 study of Dimebon and donepezil combination therapy for Alzheimer's disease

April 15, 2009

Pfizer and Medivation, Inc announced the initiation of a 12-month, Phase 3 trial of the investigational drug Dimebon in combination with donepezil HCl for the treatment of mild-to-moderate Alzheimer's disease (AD).

Phase 1 study of MCD-386 for Alzheimer's disease

April 08, 2009

Mithridion, Inc. announced results from a Phase 1 study of MCD-386, its lead drug candidate for Alzheimer's disease (AD).

Axona available for Alzheimer's disease

March 03, 2009

Axona (caprylidene, from Accera) has been launched as a medical food for the dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease (AD).